India Glycols Targets INR500cr Spirits EBITDA in FY27

India Glycols Limited — Q1 FY27 Earnings Call (held 14 Aug 2026)

1. Overall Tone of Management: Optimistic

• Management repeatedly characterizes the quarter as “very strong start” and “tremendous growth.”
• They give quantitative FY27 targets (e.g., Spirits EBITDA “in excess of INR500 crores”) and multi-year aspirations (debt-free “from FY’28 onwards”, EBITDA “in excess of INR1,000 crores” in 4–5 years).
• Even when discussing war/macro, they frame it as “both a combination of headwinds and tailwinds” with net positive implications for some businesses (e.g., EO competitiveness).

2. Key Themes from Management Commentary

• Strong consolidated Q1 performance + margin recovery narrative
• Net revenue INR1,130 crores (+9%), EBITDA INR170 crores (+13%), PAT INR170? (PAT up 32% stated).
• Margin recovery shown as a multi-year trend: EBITDA margin rising from 9.6% (FY22) → 15.5% (FY26).
• Restructuring / demerger execution
• “NCLT approval” received; scheme sanctioned 17 July 2026; demerger into three entities (IGL Chemicals, IGL Spirits, Ennature Bio Pharma) upon effectiveness.
• Management emphasizes focus and clarity post-trifurcation (consumer vs B2B dynamics).
• Spirits: premiumization + geographic/channel expansion
• Spirits (IGL Spirits) delivered net revenue INR694 crores and EBITDA INR120 crores, margin 17.3%.
• IMFL growth highlighted as the key engine: IMFL net revenue +26%, 1.4 million cases (+55%); management expects launches and share gains.
• Chemicals: resilience with specialty-led strategy; performance chemicals pipeline
• Chemicals revenue INR362 crores (+20.6%); gases small but strong margin.
• Performance chemicals growth acknowledged as below target due to exports to Middle East and raw material price/supply volatility.
• Ennature Bio Pharma: “best-ever quarter” driven by acquisitions + nicotine expansion
• Revenue INR90 crores (+53%), EBITDA INR10 crores (~100% growth).
• Growth drivers: “new acquisitions of customers,” “nutraceutical launches,” “expansion of the nicotine business,” and “improved efficiency.”
• War/macro impacts: freight volatility and input availability
• Crude spike and rupee weakness; freights “5 to 20 times” cited as a major distortion.
• Positive: crude/EO competitiveness improved for bio-based EO.
• Negative: propylene oxide availability/price hurt oil & gas specialty chemicals; exports to Middle East “collapsed” due to lack of sales activity.

3. Q&A Analysis

Theme A: FY27 guidance / outlook for Potable Spirits

• Core question(s):
• Analyst asked for “guidance for Potable Spirits for this financial year and the next financial year” (numbers + performance).
• Management response:
• FY27 Spirits EBITDA: “in excess of INR500 crores” (and “INR120 crores delivered in Q1”).
• Volume: “doubling our volume from what we delivered last year.”
• Next year: expects “healthy double digits” growth (qualitative).
• Evasive/partial elements:
• No explicit FY28 EBITDA/volume number; “next year” remains qualitative (“healthy double digits”).

Theme B: Capex / NSU segment ramp-up and profitability

• Core question(s):
• Capex planned for NSU; how it scales with new products; NSU “pillars” and ballpark.
• Management response:
• Capex: “not a huge amount… perhaps INR5–10 crores, maybe INR15–20 crores.”
• NSU aspiration: “INR150 crores plus in this year” and “INR600–700 crores” in 4–5 years.
• Profitability: expects gross margins “closer to about 30%” in ~5–6 years; current business close to 16–17%.
• Evasive/partial elements:
• Repeated “aspiration” framing; limited disclosure on exact ramp mechanics beyond modular expansion.

Theme C: JV performance sustainability + drivers

• Core question(s):
• How sustainable are JV profitability improvements (profit jump vs last year/quarter)?
• What drives JV performance going forward?
• Management response:
• JV improvement attributed to reduced EO pricing disadvantage and mix improvements; exports thrust.
• Sustainability defended: INR21 crores this quarter not “out of the blue”; also references PAT comparison.
• Notable strength/credibility signal:
• Management directly addresses sustainability but still relies on “tailwinds” and scenario-based competitiveness.

Theme D: Spirits segment details: case mix, revenue vs volume, IMFL share

• Core question(s):
• Prestige & Above cases and FY26 IMFL revenue/cases.
• Why revenue didn’t grow proportionately vs case growth (premiumization vs volume).
• IMFL % of Potable Spirits revenue and IMFL vs country liquor EBITDA margin.
• Management response:
• Prestige & Above: “~0.5 million cases… almost double of last year.”
• FY26 IMFL revenue: management said they would “get back” (not provided on call).
• Revenue vs volume: explained by brand mix and state mix (Delhi growth weaker; mass-premium growing faster).
• IMFL revenue share: “in excess of 30%.”
• EBITDA margin: avoided a clean split; said “gross margins… almost the same” for deluxe/semi-premium whiskey (and did not provide a numeric IMFL vs country liquor margin).
• Evasive/partial elements:
• Missing FY26 IMFL revenue number (promised follow-up).
• IMFL vs country liquor EBITDA margin not quantified.

Theme E: Demerger benefits / operational efficiency

• Core question(s):
• What benefit from demerger—specifically operational efficiency?
• Management response:
• Multi-fold: consumer business dynamics vs B2B; investor clarity and appetite segmentation.
• Evasive/partial elements:
• Operational efficiency remains conceptual; no quantified cost savings or timeline.

Theme F: Ennature Bio Pharma margin volatility drivers

• Core question(s):
• Q2/Q3 margin volatility and what drives EBITDA changes.
• (Related) raw material volatility in Q2.
• Management response:
• EBITDA quarter-to-quarter distortion explained by dividend income timing (Clariant dividend in prior quarter).
• Bio Pharma: raw material availability/pricing “volatile and a challenge in Q2 as well.”
• Notable strength:
• Clear accounting/timing explanation for EBITDA swings.

4. Guidance / Outlook

Explicit guidance (quantitative)

• IGL Spirits (Potable Spirits + Bio-fuel within Spirits entity)
• FY27 Spirits EBITDA: “in excess of INR500 crores”
• FY27 volume: “doubling our volume from what we delivered last year”
• FY27 outlook for next year: “healthy double digits” (qualitative, but tied to next year growth expectation)
• IGL Spirits debt-free / multi-year
• Debt-free: “from FY’28 onwards”
• EBITDA target: “in excess of INR1,000 crores in the next four to five years”
• NSU / Chemicals (Saket question)
• Capex: INR5–10 crores, “maybe INR15–20 crores” (current year)
• NSU revenue aspiration: INR150 crores plus in this year
• NSU revenue aspiration: INR600–700 crores in 4–5 years
• Gross margin aspiration: ~30% in 5–6 years
• Ennature Bio Pharma
• EBITDA aspiration: INR130–150 crores over next 4–5 years (explicitly called “aspiration, not projection”)

Implicit signals (qualitative)

• Premiumization is expected to continue to lift margins (management repeatedly links margin recovery to premium mix and launches).
• Chemicals performance chemicals pipeline expected to keep driving growth “year-on-year,” despite acknowledging export/raw material disruptions.
• War impact framed as manageable via competitiveness shifts (bio-based EO advantage) but with ongoing freight/input volatility risk.
• Demerger expected to improve focus and investor clarity; operational efficiency benefits not quantified.

5. Standout Statements (direct / highly revealing)

• Spirits FY27 EBITDA target: “We expect to deliver an EBITDA in excess of INR500 crores.”
• Spirits volume target: “we are looking at doubling our volume from what we delivered last year.”
• Debt-free timeline: “becoming a debt-free company from FY’28 onwards.”
• Multi-year Spirits EBITDA ambition: “targeting an EBITDA in excess of INR1,000 crores in the next four to five years.”
• Chemicals performance chemicals under-target admission: performance chemicals growth “lower than what we had targeted” due to exports/raw material issues.
• War/freight magnitude: “freights… going up anywhere between 5 to 20 times.”
• JV sustainability framing: “by and large… as per plan or perhaps better despite the significant headwinds.”
• Demerger benefits framed as investor/strategy clarity: “many people want much better clarity on what they are investing in rather than a mix.”
• Operational efficiency not quantified: demerger efficiency described as “multi-fold” without cost numbers.

6. Red Flags / Positive Signals

Red flags
– “Aspiration vs projection” repeated for major multi-year targets (Spirits EBITDA, NSU revenue, Bio Pharma EBITDA). This reduces enforceability.
– Incomplete disclosure in Q&A
– FY26 IMFL revenue not provided (promised follow-up).
– IMFL vs country liquor EBITDA margin not quantified.
– Next-year guidance remains qualitative (“healthy double digits”) rather than numeric.
– Operational efficiency from demerger not quantified—could be a narrative gap.

Positive signals
– Clear accounting explanation for EBITDA swings (Clariant dividend timing).
– Multiple segment beat in Q1 with consistent margin recovery narrative.
– Debt reduction progress continues (finance costs down sharply in Q1 FY27: INR25 crores vs INR45 crores in Q1 FY26).
– Concrete FY27 Spirits EBITDA + volume targets (more specific than prior calls often provide).

7. Historical Comparison & Consistency Analysis (vs prior 3 calls)

a. Change in Tone Over Time

• Current (Q1 FY27): more confident and target-heavy—gives FY27 EBITDA “in excess of INR500 crores,” debt-free timeline, and multi-year EBITDA > INR1,000 crores.
• Prior calls (Q4/FY26, Q3/9M FY26, Q2/H1 FY26):
• Management was optimistic but more focused on margin recovery trend and debt reduction, with fewer “entity-level” quantified targets.
• Shift classification: More Optimistic
• Language moved from “expectations” and “strategy” to explicit numeric aspirations tied to the demerger structure.

b. Tracking Past Commitments vs Outcomes

Using only what is explicitly stated in the provided prior transcripts:

• Debt reduction / interest cost reduction
• Prior: Q3 FY26 and Q4 FY26 emphasized prepayment and interest reduction trajectory.
• Current: finance costs down to INR25 crores in Q1 FY27 from INR45 crores in Q1 FY26.

• ✅ Delivered (directionally consistent and quantified improvement).

• Performance chemicals pipeline growth

• Prior: repeated confidence that performance chemicals would grow and become significant.
• Current: still confident, but admits performance chemicals growth “lower than what we had targeted” due to exports/raw material issues.

• ⏳ Delayed / Under-delivered vs target (not necessarily vs long-term thesis, but vs stated target).

• Demerger timeline

• Prior calls discussed demerger as a coming event (NCLT process).
• Current: “NCLT approval” and scheme sanctioned 17 July 2026; effectiveness pending.
• ✅ Delivered (approval achieved; effectiveness still “to be communicated”).

c. Narrative Shifts

• New emphasis on “trifurcation clarity” (consumer vs B2B dynamics; investor segmentation). This is more prominent than earlier calls.
• Spirits story becomes more “launch + share + channel expansion” driven with specific IMFL case growth and brand partnerships (Amrut distribution).
• Chemicals narrative shifts from “margin improvement via discontinuation” (earlier) to “specialty-led innovation + resilience,” while still acknowledging export/raw material disruptions.

d. Consistency & Credibility Signals

• Medium credibility (improving but still aspiration-heavy)
• Positives: consistent margin recovery trend and debt reduction; clear explanations for EBITDA timing.
• Concerns: repeated use of “aspiration/not projection” for large multi-year numbers; some Q&A gaps (missing FY26 IMFL revenue; no quantified demerger efficiency).

e. Evolution of Key Themes

• Margins: Improving/stable (FY22 9.6% → FY26 15.5%; Q1 FY27 margin strength continues).
• Premiumization: Strengthening (now tied to IMFL case growth, launches, and state mix).
• Bio-fuels: Stable policy-driven framing; war/macro impacts acknowledged but profitability framed as “range-bound by policy.”
• Chemicals: Specialty-led innovation remains, but execution variability shows up (performance chemicals below target).

f. Additional Insights (cross-period intelligence)

• Risk is becoming more explicit in Q1 FY27 via freight volatility quantification (“5 to 20 times”) and raw material availability constraints (propylene oxide).
• Defensiveness in Q&A is moderate: management often answers with “reasons” but avoids hard splits (IMFL vs country liquor margins; demerger efficiency quantification).
• Targets are now more aggressive post-restructuring—suggesting management believes the new structure will unlock clearer execution and investor confidence, but enforceability remains limited due to “aspiration” language.